Clinical trials: Cancer of the Liver
Advanced Hepatocellular Carcinoma
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced…
- Trial name
- NCT04000737
- Testing
- Sorafenib+YIV-906
- Where
- 24 sites in United States, China and 2 more
- Volunteers
- 62 people
- Sponsor
- Yiviva Inc.
Ovarian, Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid…
- Conditions
- Ovarian, Melanoma, Renal, Prostate
- Trial name
- NCT00423254
- Testing
- PSMA/PRAME
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mannkind Corporation
Hepatocellular Carcinoma (HCC)
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
The primary objective of the study is to assess the time to progression (TTP) in patients with advanced HCC treated with Icaritin .
- Trial name
- NCT01972672
- Testing
- Icaritin
- Where
- 3 sites in China
- Volunteers
- 70 people
- Sponsor
- Beijing Shenogen Biomedical Co., Ltd
Carcinoma, Hepatocellular, Liver Neoplasms
Laser Interstitial Thermal Therapy Under "Real Time" MRI Guidance for "Minimal Invasive" Treatment of Liver Metastasis
The purpose of this study is to determine if the, MR guided, laser interstitial thermal therapy (LITT) treatment technique can be safety and efficiently used for the human liver metastasis
- Conditions
- Carcinoma, Hepatocellular, Liver Neoplasms, Digestive System Neoplasms
- Trial name
- NCT00392366
- Testing
- MR-guided Laser Interstitial Thermal Therapy System
- Where
- France
- Volunteers
- 25 people
- Sponsor
- BioTex, Inc.
Renal Cell Carcinoma, Hepatocellular Carcinoma
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of…
- Conditions
- Renal Cell Carcinoma, Hepatocellular Carcinoma, Differentiated Thyroid Carcinoma
- Trial name
- NCT03776123
- Where
- 47 sites in South Korea
- Volunteers
- 347 people
- Sponsor
- Ipsen
Locally Advanced Liver Carcinoma
A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer
The goal of this clinical trial is to investigate the BST02, a tumor infiltrating lymphocyte product, collected from the locally advanced liver cancer subjects The main questions it aims to answer are: 1.
- Trial name
- NCT06526832
- Testing
- BST02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- BioSyngen Pte Ltd
Carcinoma, Hepatocellular
Sorafenib for Residue Disease After Resection With Curative Intent
Radical hepatic resection represents one of the treatment options offering a prospect for cure with 5-year survival rates up to 50%.
- Trial name
- SECURE (NCT01751763)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
c-Met Second-Line Hepatocellular Carcinoma
This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A…
- Trial name
- NCT02115373
- Testing
- Tepotinib
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Carcinoma, Metastases
Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are: to evaluate the safety and any harmful effects of an intravenous injection of…
- Trial name
- NCT00107861
- Testing
- Ad.hIFN-β (BG00001, IDEC-201)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Biogen
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Hepatocellular Carcinoma (HCC)
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease.
- Trial name
- NCT06487559
- Testing
- Livmoniplimab, Budigalimab
- Where
- 11 sites in China
- Volunteers
- 3 people
- Sponsor
- AbbVie
Triple Negative Breast Cancer, Hepatocellular Carcinoma
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable…
- Trial name
- NCT03318562
- Testing
- eFT508
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Effector Therapeutics
HepatoCellular Carcinoma, Portal Vein Tumor Thrombosis
Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
This is a phase I/II dose-escalation study of lipotecan based concurrent chemoradiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
- Trial name
- NCT03035006
- Testing
- Lipotecan
- Where
- 4 sites in Taiwan
- Volunteers
- 1 people
- Sponsor
- Taiwan Liposome Company
Neoplasm Metastasis, Liver Neoplasms
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
This clinical trial evaluated the safety and tolerability of CRS-100, an investigational agent containing a live-attenuated strain of Listeria monocytogenes (Lm).
- Conditions
- Neoplasm Metastasis, Liver Neoplasms, Carcinoma
- Trial name
- NCT00327652
- Testing
- CRS-100
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Anza Therapeutics, Inc.
Hepatocellular Carcinoma, Liver Metastases
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
- Trial name
- NCT04676633
- Testing
- STP705
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sirnaomics
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Study of rSIFN-co in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, phase I study of rSIFN-co (3 times a week via subcutaneous injection for 21 days, with 1 week of washout per cycle).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Carcinoma, Hepatocellular
- Trial name
- rSIFN-01 (NCT02387307)
- Testing
- rSIFN-co
- Where
- Singapore
- Volunteers
- 42 people
- Sponsor
- Sichuan Huiyang Life Science and Technology Corporation
Hepatocellular Carcinoma
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
The purpose of this study is to determine whether patients with hepatocellular carcinoma who receive either E7050 administered with Sorafenib or Sorafenib alone experience greater benefit (cancer responds to treatment) when E7050…
- Trial name
- NCT01271504
- Testing
- Sorafenib
- Where
- 24 sites in United States, Belgium and 4 more
- Volunteers
- 102 people
- Sponsor
- Eisai Inc.
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
- Conditions
- Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT04374877
- Testing
- CHS-388, Pembrolizumab, Toripalimab
- Where
- 23 sites in United States, Singapore and 1 more
- Volunteers
- 145 people
- Sponsor
- Coherus Oncology, Inc.
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.